Skip to main content
Erschienen in: Neurological Sciences 3/2017

01.03.2017 | Original Article

Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis

verfasst von: Xiaohui Hu, Yan Yang, Daokai Gong

Erschienen in: Neurological Sciences | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

As a biomarker of axonal injury, neurofilament light chain (NFL) in multiple system atrophy (MSA) patients and Parkinson’s disease (PD) patients has been investigated by numerous studies. However, cerebrospinal fluid (CSF) NFL changes are conflicting in MSA patients relative to PD patients to date. Therefore, the current study was carried out to find out possible heterogeneity sources. Furthermore, “Neurofilament”, “Neurofilament light chain” and “Multiple system atrophy” were employed to search “PubMed”, “Springer” and “Medline” databases until August 2016 with standard mean difference (Std.MD) being calculated. In addition, subgroup analysis and meta-regression were performed to assess possible heterogeneity sources. Nine studies were pooled, in which 212 MSA patients and 373 PD patients were involved. Moreover, CSF NFL in MSA patients was higher than that in PD patients [pooled Std.MD = 1.56, 95% CI (1.12, 2.00), p < 0.00001] with significant heterogeneity (I 2 = 76%). Besides, population variations, sample size, the difference in CSF phosphorylated tau (p-tau) levels between MSA patients and PD patients, and Hoehn–Yahr staging of PD patients were the main heterogeneity sources. As shown by meta-regression, Hedges’s g of CSF NFL was correlated with CSF Std.MD of α-synuclein between MSA patients and healthy controls (r = −1.34824, p = 0.00025). Therefore, CSF NFL increased in MSA patients relative to PD patients. Meta-regression showed that NFL was associated with α-synuclein in CSF of MSA patients relative to healthy controls. Due to the influence of heterogeneity sources, more prospective large sample studies are still needed to assess CSF NFL changes in MSA patients relative to PD patients.
Literatur
1.
Zurück zum Zitat Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL (2013) Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease. Brain Pathol 23:263–273CrossRefPubMed Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL (2013) Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy, progressive supranuclear palsy and Parkinson’s disease. Brain Pathol 23:263–273CrossRefPubMed
2.
Zurück zum Zitat Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T et al (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38:4–24CrossRefPubMed Ahmed Z, Asi YT, Sailer A, Lees AJ, Houlden H, Revesz T et al (2012) The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol 38:4–24CrossRefPubMed
3.
Zurück zum Zitat Stefanova N, Bucke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178CrossRefPubMed Stefanova N, Bucke P, Duerr S, Wenning GK (2009) Multiple system atrophy: an update. Lancet Neurol 8:1172–1178CrossRefPubMed
4.
Zurück zum Zitat Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK (2012) Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol 124:51–65CrossRefPubMedPubMedCentral Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK (2012) Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol 124:51–65CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W et al (2014) Towards translational therapies for multiple system atrophy. Prog Neurobiol 118:19–35CrossRefPubMedPubMedCentral Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W et al (2014) Towards translational therapies for multiple system atrophy. Prog Neurobiol 118:19–35CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Shimohata T, Aizawa N, Nakayama H, Taniguchi H, Ohshima Y, Okumura H et al (2016) Mechanisms and prevention of sudden death in multiple system atrophy. Parkinsonism Relat Disord 30:1–6CrossRefPubMed Shimohata T, Aizawa N, Nakayama H, Taniguchi H, Ohshima Y, Okumura H et al (2016) Mechanisms and prevention of sudden death in multiple system atrophy. Parkinsonism Relat Disord 30:1–6CrossRefPubMed
7.
Zurück zum Zitat Sako W, Murakami N, Izumi Y, Kaji R (2014) The difference in putamen volume between MSA and PD: evidence from a meta-analysis. Parkinsonism Relat Disord 20:873–877CrossRefPubMed Sako W, Murakami N, Izumi Y, Kaji R (2014) The difference in putamen volume between MSA and PD: evidence from a meta-analysis. Parkinsonism Relat Disord 20:873–877CrossRefPubMed
8.
Zurück zum Zitat Wang PS, Wu HM, Lin CP, Soong BW (2011) Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy. Neuroradiology 53:471–481CrossRefPubMed Wang PS, Wu HM, Lin CP, Soong BW (2011) Use of diffusion tensor imaging to identify similarities and differences between cerebellar and Parkinsonism forms of multiple system atrophy. Neuroradiology 53:471–481CrossRefPubMed
9.
Zurück zum Zitat Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A et al (2015) Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol Dis 80:29–41CrossRefPubMed Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A et al (2015) Fluid biomarkers in multiple system atrophy: a review of the MSA Biomarker Initiative. Neurobiol Dis 80:29–41CrossRefPubMed
10.
Zurück zum Zitat Bäckström DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M et al (2015) Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurol 72:1175–1182CrossRefPubMed Bäckström DC, Eriksson Domellof M, Linder J, Olsson B, Ohrfelt A, Trupp M et al (2015) Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease. JAMA Neurol 72:1175–1182CrossRefPubMed
11.
Zurück zum Zitat Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson’s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352:84–87CrossRefPubMed Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson’s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352:84–87CrossRefPubMed
12.
Zurück zum Zitat Sterne J, Moher D, and (editors)(2011) Chapter 10:addressing reporting biases.2011.In:Cochrane hand-book for systematic reviews of intervention version 510(updated March 2011)[Internet]. The Cochrane Collaboration Available from www.cochrane-handbool.org Sterne J, Moher D, and (editors)(2011) Chapter 10:addressing reporting biases.2011.In:Cochrane hand-book for systematic reviews of intervention version 510(updated March 2011)[Internet]. The Cochrane Collaboration Available from www.​cochrane-handbool.​org
13.
Zurück zum Zitat Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed
14.
Zurück zum Zitat Holmberg B, Rosengren L, Karlsson JE, Johnels B (1998) Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov Disord 13:70–77CrossRefPubMed Holmberg B, Rosengren L, Karlsson JE, Johnels B (1998) Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov Disord 13:70–77CrossRefPubMed
15.
Zurück zum Zitat Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L (2001) CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 8:23–31CrossRefPubMed Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L (2001) CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 8:23–31CrossRefPubMed
16.
Zurück zum Zitat Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging 28:742–747CrossRefPubMed Abdo WF, Bloem BR, Van Geel WJ, Esselink RA, Verbeek MM (2007) CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease. Neurobiol Aging 28:742–747CrossRefPubMed
17.
Zurück zum Zitat Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B (2010) Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 16:142–145CrossRefPubMed Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B (2010) Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson’s disease and atypical Parkinsonian disorders. Parkinsonism Relat Disord 16:142–145CrossRefPubMed
18.
Zurück zum Zitat Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jorgensen HL et al (2012) Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 18:69–72CrossRefPubMed Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jorgensen HL et al (2012) Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat Disord 18:69–72CrossRefPubMed
19.
Zurück zum Zitat Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69:1445–1452CrossRefPubMed Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F et al (2012) Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 69:1445–1452CrossRefPubMed
21.
Zurück zum Zitat Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86:1240–1247CrossRefPubMedPubMedCentral Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K et al (2015) A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 86:1240–1247CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE et al (2014) Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34:12368–12378CrossRefPubMed Sacino AN, Brooks M, McKinney AB, Thomas MA, Shaw G, Golde TE et al (2014) Brain injection of alpha-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci 34:12368–12378CrossRefPubMed
23.
Zurück zum Zitat Shea TB, Lee S (2011) Neurofilament phosphorylation regulates axonal transport by an indirect mechanism: a merging of opposing hypotheses. Cytoskeleton (Hoboken) 68:589–595CrossRef Shea TB, Lee S (2011) Neurofilament phosphorylation regulates axonal transport by an indirect mechanism: a merging of opposing hypotheses. Cytoskeleton (Hoboken) 68:589–595CrossRef
24.
Zurück zum Zitat Teunissen CE, Khalil M (2012) Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 18:552–556CrossRefPubMed Teunissen CE, Khalil M (2012) Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 18:552–556CrossRefPubMed
25.
Zurück zum Zitat Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A et al (2015) Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 86:273–279CrossRefPubMed Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A et al (2015) Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry 86:273–279CrossRefPubMed
26.
Zurück zum Zitat Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA et al (2016) Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91:56–66CrossRefPubMed Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA et al (2016) Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 91:56–66CrossRefPubMed
27.
Zurück zum Zitat Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A et al (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2:748–755CrossRefPubMedPubMedCentral Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A et al (2015) CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2:748–755CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al (2013) Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70:1277–1287PubMedPubMedCentral Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS et al (2013) Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 70:1277–1287PubMedPubMedCentral
29.
Zurück zum Zitat Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study. Acta Neuropathol 131:935–949CrossRefPubMed Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR et al (2016) CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study. Acta Neuropathol 131:935–949CrossRefPubMed
Metadaten
Titel
Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson’s disease: a meta-analysis
verfasst von
Xiaohui Hu
Yan Yang
Daokai Gong
Publikationsdatum
01.03.2017
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe 3/2017
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-016-2783-7

Weitere Artikel der Ausgabe 3/2017

Neurological Sciences 3/2017 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Demenzkranke durch Antipsychotika vielfach gefährdet

Demenz Nachrichten

Der Einsatz von Antipsychotika gegen psychische und Verhaltenssymptome in Zusammenhang mit Demenzerkrankungen erfordert eine sorgfältige Nutzen-Risiken-Abwägung. Neuen Erkenntnissen zufolge sind auf der Risikoseite weitere schwerwiegende Ereignisse zu berücksichtigen.

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.